(Q34398107)

English

Bapineuzumab

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

Bapineuzumab (English)

1 reference

Europe PubMed Central

1 August 2017

2

object named as

Adam L Boxer

1 reference

Europe PubMed Central

1 August 2017

author name string

Geoffrey A Kerchner

1

1 reference

Europe PubMed Central

1 August 2017

language of work or name

0 references

publication date

1 July 2010

1 reference

Europe PubMed Central

1 August 2017

Expert Opinion on Biological Therapy

1 reference

Europe PubMed Central

1 August 2017

10

1 reference

Europe PubMed Central

1 August 2017

7

1 reference

Europe PubMed Central

1 August 2017

1121-1130

1 reference

Europe PubMed Central

1 August 2017

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

mAbs: a business perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Applications of neuroimaging to disease-modification trials in Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

The role of apolipoprotein E in Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Cholinesterase inhibition: is there evidence for disease-modifying effects?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Developing novel immunogens for a safe and effective Alzheimer's disease vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Update on the use of memantine in Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Bridging physiology and pathology in AD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

The amyloid hypothesis for Alzheimer's disease: a critical reappraisal

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Development of AFFITOPE vaccines for Alzheimer's disease (AD)--from concept to clinical testing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

A beta oligomers - a decade of discovery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

6 July 2018

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.493872

21 January 2018

Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.493872

21 January 2018

Antibody against C-terminal Abeta selectively elevates plasma Abeta.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.493872

21 January 2018

Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.493872

21 January 2018

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.493872

21 January 2018

Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.493872

21 January 2018

Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.493872

21 January 2018

Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.493872

21 January 2018

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.493872

21 January 2018

Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.493872

21 January 2018

Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.493872

21 January 2018

Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.493872

21 January 2018

Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.493872

21 January 2018

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.493872

21 January 2018

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.493872

21 January 2018

APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.493872

21 January 2018

Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000430

27 October 2018

Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.493872

21 January 2018

Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse

1 reference

https://pubmed.ncbi.nlm.nih.gov/20497044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'?

1 reference

https://pubmed.ncbi.nlm.nih.gov/20497044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1517/14712598.2010.493872

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34398107&oldid=1979599468"